TheraRadar
← Back
Data updated: Nov 8, 2026

SOLGEN

Generics

SOLGEN is a generic drug manufacturer focused on Respiratory, Dermatology.

2008
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

SOLGEN's Key Drugs

SOLGEN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SOLGEN's Recent FDA Approvals

New NDA/BLA approvals for SOLGEN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SOLGEN's Therapeutic Areas

SOLGEN's approved drugs and pipeline span 2 therapeutic areas, led by Respiratory and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 50%
1 drugs
Dermatology 50%
1 drugs

SOLGEN's Top Competitors

SOLGEN's closest competitors by therapeutic-area and drug-target overlap include Bayer, PHARMACIA AND UPJOHN, and MALLINCKRODT. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SOLGEN Pipeline Snapshot

Active clinical trials for SOLGEN across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling